Table 1

Baseline demographics and disease characteristics

Characteristic, mean±SD*Adalimumab
Age, years40.6±11.9
Women, n (%)90 (55)
BMI (kg/m2)26.6±5.8
Smoker, yes, n (%)39 (24)
Symptom duration, years7.24±7.1
HLA-B27-positive, n (%)103 (63)
Prior DMARD use, n (%)115 (70)
Concomitant DMARD use, n (%)79 (48)
Elevated hs-CRP, n (%)72 (44)
Swollen joint count (0–76)6.7±6.9
Tender joint count (0–78)13.3±14.5
Physician Global Assessment of disease activity (0–100)58.7±15.3
Patient Global Assessment of pain (0–100)64.9±14.9
Patient Global Assessment of disease activity (0–100)65.8±15.5
Enthesitis count (0–29)7.0±6.8
Dactylitis count (0–20)0.5±1.1
BASDAI (0–10)5.62±1.7
  • *Unless otherwise noted.

  • †n=164.

  • ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BMI, body mass index; DMARD, disease-modifying antirheumatic drug; HLA, human leucocyte antigen; hs-CRP, high-sensitivity C-reactive protein.